In an elderly patient with dementia and anxiety taking citalopram 10 mg by mouth daily, donepezil 10 mg by mouth daily, and memantine 5 mg twice daily, with an estimated glomerular filtration rate of 26 mL/min/1.73 m² and serum creatinine 1.76 mg/dL, should the medication doses be continued as prescribed or adjusted?

Medication Dose Adjustments in Severe CKD (eGFR 26)

You need to reduce the memantine dose immediately to 5 mg once daily (instead of 5 mg twice daily), while citalopram 10 mg daily and donepezil 10 mg daily can be continued at current doses.

Memantine Dose Reduction Required

With an eGFR of 26 mL/min/1.73 m², this patient has Stage 4 CKD (severe renal impairment). Memantine requires dose adjustment in severe renal impairment 1. The consensus guideline specifically identifies memantine as one of eight medications requiring "specific recommendations for dose reduction or interval extension" in elderly patients with reduced renal function 1.

• Current dose: 5 mg BID (10 mg/day total)
• Adjusted dose: 5 mg once daily (5 mg/day total)
• Rationale: Memantine is primarily renally cleared, and accumulation occurs with eGFR <30 mL/min

The FDA labeling for memantine (though not provided in your evidence) typically recommends dose reduction to 5 mg twice daily for moderate impairment (eGFR 30-49) and 5 mg once daily for severe impairment (eGFR <30). Your patient falls into the severe category.

Donepezil - No Dose Adjustment Needed

Donepezil 10 mg daily does not require dose adjustment despite the severe renal impairment 2. The FDA labeling for donepezil makes no mention of renal dose adjustments, as donepezil is primarily metabolized hepatically via CYP2D6 and CYP3A4, not renally cleared 3.

• Small case series in chronic hemodialysis patients demonstrated that donepezil at 2.5-5 mg daily was well-tolerated without toxicity 3
• Your patient's dose of 10 mg daily is standard and appropriate
• Monitor for cholinergic side effects (nausea, diarrhea, bradycardia) but these are not specifically related to renal function 2

Important caveat: The 2021 Mayo Clinic guideline suggests considering deprescribing cholinesterase inhibitors in advanced dementia due to "lacking long-term benefit, particularly in advanced dementia" 4. However, without knowing the severity of this patient's dementia, continuation is reasonable if there's perceived benefit.

Citalopram - No Dose Adjustment for Renal Function

Citalopram 10 mg daily does not require dose adjustment based on renal impairment alone 5. Citalopram is primarily hepatically metabolized, and the FDA labeling does not specify renal dose adjustments 5.

• The current dose of 10 mg daily is already at the lower end of the therapeutic range (typical dosing 20-40 mg daily)
• Critical consideration: Maximum dose should not exceed 20 mg daily in patients >60 years old due to QT prolongation risk 5
• Monitor electrolytes (potassium, magnesium) as hypokalemia/hypomagnesemia increase QT risk, particularly relevant given the CKD 5

Additional Monitoring for Citalopram

Given the CKD and elderly status:

• Watch for hyponatremia (SIADH risk with SSRIs, compounded by CKD) 5
• Consider baseline and periodic ECG monitoring given age and renal disease
• Monitor for increased bleeding risk if patient is on anticoagulants or NSAIDs 5

Practical Implementation

1. Immediate action: Reduce memantine from 5 mg BID to 5 mg once daily
2. Continue: Donepezil 10 mg daily and citalopram 10 mg daily unchanged
3. Monitor: Electrolytes (Na, K, Mg), cognitive/behavioral response, and cholinergic side effects
4. Reassess: Consider deprescribing donepezil if dementia is advanced with no perceived benefit 4

Common Pitfalls to Avoid

• Don't assume all medications need renal adjustment: Only memantine requires adjustment among these three drugs
• Don't use serum creatinine alone: The eGFR of 26 correctly identifies severe impairment despite creatinine of only 1.76 (likely due to reduced muscle mass in elderly) 6
• Don't overlook QT risk: Elderly patients with CKD and electrolyte abnormalities on citalopram need cardiac monitoring 5
• Don't continue ineffective medications: If the dementia is advanced and donepezil shows no benefit, consider tapering off 4